在患有心房的患者中进行密尔维克斯III期研究的量化模型选择
Wangda Zhou1, Emily Bozenhardt1, Gregory E Alexander2
1Johnson & Johnson, Raritan, New Jersey, USA.
Clinical pharmacology and therapeutics
|August 22, 2025
概括
作为一种新型XI因子抑制剂,Milvexian对预防心房患者的血栓事件具有前景. 在LIBREXIA AF试验的模拟中,每天两次使用100 mg的剂量显示出良好的疗效和安全性.
科学领域:
- 药理学和血栓形成研究
- 临床试验设计和建模
背景情况:
- 米尔维西安是一种正在研究中的激活因子XI抑制剂.
- 在LIBREXIA第三阶段计划中,正在评估milvexian用于预防血栓事件,包括心房动 (AF).
研究的目的:
- 在心房患者中确定milvexian的最佳III期剂量方案.
- 描述米尔韦西安的疗效,安全性和生物标志物的暴露-反应关系.
主要方法:
- 使用I期和II期数据进行群体药理学和暴露反应建模.
- 对骨科手术患者的比较抗凝剂进行基于模型的分析.
- 在AF群体中预测疗效和安全性的模拟.
主要成果:
- 每日两次100毫克的milvexian疗法显示,模拟静脉血栓栓塞率为9. 4%,低于埃诺沙.
- 没有观察到milvexian暴露与出血事件之间的相关性.
- 在AF患者中,与apixaban相比,模拟全身血栓发生率为0. 84.
结论:
- 基于模型的综合方法支持每天两次服用100毫克的milvexian用于LIBREXIA AF第三阶段研究.
- 这种剂量方案似乎为AF中风预防提供了有利的疗效与安全平衡.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
149
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
149
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
137
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
137


